Moderna (MRNA) Stock Drops 17% Despite Melanoma Trial Success

TLDR Moderna stock plunged more than 17% to $202.63 after early publication of its melanoma vaccine trial results. The Merck-Moderna treatment reduced melanoma recurrence or death risk by 42% and distant spread or death risk by 38%. Two-year recurrence-free survival reached 82.2% with the combined treatment, compared with 70% for Keytruda alone. Moderna and Merck [...]

The post Moderna (MRNA) Stock Drops 17% Despite Melanoma Trial Success appeared first on Blockonomi.